Charles River Laboratories International (CRL)

NYSE Market Closed

Charles River Laboratories International, Inc. is a contract research and manufacturing support company serving the pharmaceutical, biotechnology, medical device, academic, and government research markets. Founded in 1947, the company plays a central role in the outsourced life sciences ecosystem by helping clients move potential therapies from early research through preclinical development and quality testing.

The business is best known for its research models and related services. Charles River supplies laboratory animal models with defined genetic and health characteristics, along with specialized services that support preclinical studies. These models are used by researchers to study disease biology, evaluate drug candidates, and generate data before human clinical trials begin.

Beyond research models, Charles River offers discovery and safety assessment services. This part of the company supports drug developers with activities such as target validation, pharmacology, toxicology, and other studies required to assess whether a compound is suitable for further development. By providing these services externally, the company allows customers to access scientific expertise and infrastructure without building all capabilities in-house.

Charles River also operates a manufacturing support segment that includes microbial testing products, biologics testing services, and avian vaccine services. These offerings help customers confirm product safety, quality, and regulatory compliance, particularly in biologics and advanced therapies.

The company’s position is distinctive because it spans multiple stages of the research and development process. Its customers rely on it not only for laboratory models, but also for scientific services and quality-control tools that are embedded in drug discovery, preclinical testing, and biomanufacturing workflows.

181.34 USD
176.00 USD
−4.45 (-2.40%)
After-hours

Last updated

Market Cap
8.95B
P/E
P/FCF
30.17
P/S
2.22
Enterprise Value
11.42B
Sector
Industrials
Industry
Commercial Physical and Biological Research
Address
251 BALLARDVALE ST, WILMINGTON, MA, 01887
GlobeNewswire Inc.

Cell Banking Outsourcing Market: 16%+ CAGR (2026-2031), Expanding with Rising Demand for Biologics and Regenerative Medicine Services, Says Mordor Intelligence

25 May 2026, 09:15 AM
GlobeNewswire Inc.

Global Plasmid DNA Manufacturing Market Anticipates Impressive Growth Trajectory at a CAGR of ~18% by 2034 | DelveInsight

04 May 2026, 18:00 PM
GlobeNewswire Inc.

Global AAV Vector Manufacturing Market Gearing Up for Outstanding Expansion at a CAGR of ~22% by 2034 | DelveInsight

28 Apr 2026, 18:00 PM
GlobeNewswire Inc.

Drug Development Services Market Research Report 2026: $50+ Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

14 Apr 2026, 15:59 PM
GlobeNewswire Inc.

Practical Implementation of GCP in Veterinary Course: Approaches to the Design, Set-up and Conduct in Compliance with VICH Good Clinical Practice (GCP) Principles (ONLINE EVENT: May 13th-14th, 2026)

14 Apr 2026, 09:58 AM
GlobeNewswire Inc.

[Latest] Global Adeno Associated Virus Vector Manufacturing Market Size/Share Worth USD 9.87 Billion by 2035 at a 13.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Growth Rate, Value, SWOT Analysis)

03 Feb 2026, 18:00 PM
GlobeNewswire Inc.

Lead Optimization Services in Drug Discovery Market to Reach USD 10.26 Billion by 2034, Driven by Rising R&D Activity

28 Nov 2025, 15:00 PM
GlobeNewswire Inc.

Cell & Gene Therapy Quality Control Market Poised USD 22.81 Billion at 25.74% CAGR by 2034

29 Oct 2025, 13:00 PM
GlobeNewswire Inc.

Biologics Safety Testing Market to Rise at 13.64% CAGR, Soars USD 14.45 Bn by 2034

16 Oct 2025, 16:00 PM
GlobeNewswire Inc.

Pharmaceutical Contract Research Services Market Report 2025-2035: M&A, Partnerships, and Biologics Focus

24 Sept 2025, 09:53 AM
GlobeNewswire Inc.

Global Bioanalytical Testing Services Market to Observe Stunning Growth at a CAGR of ~16% by 2032 | DelveInsight

26 Aug 2025, 18:00 PM
GlobeNewswire Inc.

Residual DNA Testing Global Market Forecast to 2030 | Novel Modalities, Emerging Markets Growth, Continuous Processing Integration, and Rising CRO/CDMO Outsourcing

05 Aug 2025, 09:35 AM
GlobeNewswire Inc.

Pharma Contract Research Organization (CRO) Services Market to Cross USD 36.66 Billion in 2025, Expanding at a CAGR of 10.04%

18 Jul 2025, 15:00 PM
Investing.com

The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?

16 Apr 2025, 14:25 PM
GlobeNewswire Inc.

Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - CRISPR and Genomic Advances are Driving Crop Innovation

11 Mar 2025, 11:46 AM
GlobeNewswire Inc.

Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight

05 Mar 2025, 18:00 PM
GlobeNewswire Inc.

Pharmaceutical Regulatory Affairs Research Report 2025-2030: Entry of Companies into the Global Market Fueling Growth

23 Jan 2025, 12:45 PM
GlobeNewswire Inc.

Clinical Trials Support Services Market Poised for Notable Expansion by 2030, Driven by Substantial Investments in R&D from Pharmaceutical and Biopharmaceutical Companies

14 Jan 2025, 15:55 PM
GlobeNewswire Inc.

Biologics Contract Manufacturing Market Industry Report 2024-2035: Mammalian Expression System is Set to Capture the Highest Share of the Market During the Forecast Period

23 Dec 2024, 17:59 PM
GlobeNewswire Inc.

Healthcare Analytical Testing Services Market to Surpass Valuation of USD 15.55 Billion by 2031 | SkyQuest Technology

16 Dec 2024, 01:00 AM
Market Cap
8.95B
Enterprise Value
11.42B
P/E
P/B
3.04
P/S
2.22
EV / EBITDA
14.34
EV / Sales
2.84
EPS
-3.83
Dividend Yield
0%
P/FCF
30.17
P/CF
14.74
Free Cash Flow
296.67M
ROE
-6.28%
ROA
-2.39%
Debt / Equity
0.91
Current Ratio
1.36
Quick Ratio
1.03
Cash
0.18
Avg Volume
924.28K
Fundamentals Snapshot Price
185.79

Income Statement

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Revenue 995.83M 994.23M 1B 1.03B 984.17M
Gross profit 294.66M 309.68M 338.79M 357.07M 317.73M
Operating income 119.9M -283.44M 133.8M 100.13M 74.67M
EBITDA 187.05M 170.81M 218.96M 219.64M 195.03M
Net income -14.84M -276.56M 54.42M 52.33M 25.47M
Basic EPS -0.3 -5.57 1.11 1.06 0.5
Diluted EPS -0.3 -5.56 1.1 1.06 0.5

Balance Sheet

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Total assets 7.73B 7.14B 7.51B 7.56B 7.58B
Total liabilities 4.74B 3.92B 4.06B 4.16B 4.34B
Total equity 2.95B 3.17B 3.41B 3.36B 3.2B
Cash & equivalents 191.83M 213.77M 207.1M 182.82M 229.36M
Current assets 1.49B 1.45B 1.53B 1.47B 1.51B
Current liabilities 1.09B 1.12B 1.12B 1.08B 1.05B

Cash Flow

Line Item 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Operating cash flow 41.08M 147.52M 213.83M 204.6M 171.7M
Investing cash flow -407.85M -92.81M -33.7M -37.34M -45.48M
Financing cash flow 347.72M -51.86M -152.62M -226.92M -105.33M
Change in cash -17.8M 6.78M 24.48M -46.99M 26.16M
Kind Filing Date Link
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
form 4 Form 4 — Barg Steven View Filing
form 4 Form 4 — Parisotto Shannon M View Filing
form 4 Form 4 — Creamer Victoria L View Filing
form 4 Form 4 — Girshick Birgit View Filing
form 4 Form 4 — Knell Michael Gunnar View Filing
form 4 Form 4 — LaPlume Joseph W View Filing
form 4 Form 4 — Mintz Mark View Filing
form 4 Form 4 — Parisotto Shannon M View Filing
form 4 Form 4 — Creamer Victoria L View Filing
form 4 Form 4 — FOSTER JAMES C View Filing
form 4 Form 4 — FOSTER JAMES C View Filing
form 4 Form 4 — FOSTER JAMES C View Filing
form 4 Form 4 — FOSTER JAMES C View Filing
form 4 Form 4 — FOSTER JAMES C View Filing
form 4 Form 4 — FOSTER JAMES C View Filing
form 4 Form 4 — FOSTER JAMES C View Filing
form 4 Form 4 — Girshick Birgit View Filing
form 4 Form 4 — Knell Michael Gunnar View Filing
form 4 Form 4 — LaPlume Joseph W View Filing
form 4 Form 4 — Mintz Mark View Filing
form 4 Form 4 — Parisotto Shannon M View Filing
form 4 Form 4 — Parisotto Shannon M View Filing
form 4 Form 4 — Parisotto Shannon M View Filing
form 4 Form 4 — Creamer Victoria L View Filing
form 4 Form 4 — Girshick Birgit View Filing
form 4 Form 4 — Girshick Birgit View Filing
form 4 Form 4 — Knell Michael Gunnar View Filing
form 4 Form 4 — LaPlume Joseph W View Filing
form 4 Form 4 — Mintz Mark View Filing
form 4 Form 4 — Coleman Glenn View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
form 4 Form 4 — LaPlume Joseph W View Filing
form 4 Form 4 — Knell Michael Gunnar View Filing
form 4 Form 4 — Girshick Birgit View Filing
form 4 Form 4 — Mintz Mark View Filing
form 4 Form 4 — Parisotto Shannon M View Filing
form 4 Form 4 — Creamer Victoria L View Filing
form 4 Form 4 — LaPlume Joseph W View Filing
form 4 Form 4 — Knell Michael Gunnar View Filing
form 4 Form 4 — Girshick Birgit View Filing
form 4 Form 4 — Girshick Birgit View Filing
form 4 Form 4 — Mintz Mark View Filing
form 4 Form 4 — Parisotto Shannon M View Filing
form 4 Form 4 — Creamer Victoria L View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
form 4 Form 4 — Andrews Nancy C View Filing
form 4 Form 4 — Andrews Nancy C View Filing
edgar index SD — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 8-K — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
edgar index 4 — CHARLES RIVER LABORATORIES INTERNATIONAL, INC. View Filing
eight k text 8-K — 8-K View Filing